BCR::ABL1

About

Gene context: ABL1, BCR

Biomarker Type: Rearrangement

Present: True

Rearrangement Type: Fusion


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Cytarabine, Methotrexate, Ponatinib, Prednisone, Vincristine FDA
Sensitivity (+) ABL1 p.T315I, BCR::ABL1 Acute Lymphoid Leukemia Ponatinib FDA
Sensitivity (+) ABL1 p.T315I, BCR::ABL1 Acute Lymphoid Leukemia Ponatinib HC
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Bosutinib HC
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Bosutinib HC
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Imatinib FDA
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Imatinib FDA
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Imatinib FDA
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Imatinib FDA
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Imatinib FDA
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Imatinib FDA
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Imatinib HC
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Imatinib HC
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Imatinib HC
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Imatinib HC
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Nilotinib FDA
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Nilotinib FDA
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Nilotinib FDA
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Nilotinib FDA
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Nilotinib FDA
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Nilotinib FDA
Sensitivity (+) BCR::ABL1, CD19 + Acute Lymphoid Leukemia Blinatumomab FDA
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Bosutinib FDA
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Bosutinib FDA
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Dasatinib FDA
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Dasatinib FDA
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Dasatinib FDA
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Dasatinib FDA
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Dasatinib FDA
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Dasatinib FDA
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Dasatinib FDA
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Dasatinib FDA
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Asciminib FDA
Sensitivity (+) ABL1 p.T315I, BCR::ABL1 Chronic Myelogenous Leukemia Asciminib FDA
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Asciminib FDA
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Asciminib FDA
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Asciminib FDA